| Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.Am J Hematol | PMID 39927501PMC11966352 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39934055无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.Ann Rheum Dis | PMID 39948001无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.Eur J Haematol | PMID 39952901PMC11976685 | 2025-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial.Am J Ophthalmol | PMID 39954920无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE.J Allergy Clin Immunol Pract | PMID 39956162无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents.J Child Adolesc Psychopharmacol | PMID 39970021无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.Lancet Rheumatol | PMID 39983751无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.Ann Oncol | PMID 39986927PMC12034480 | 2025-May | 0.90 | The record reports results from two randomized Phase III trials in human oncology with time-to-event endpoints. However, the intervention is non-drug (radiation dose escalation), and the analysis is a biomarker validation study, not a report of a drug-containing intervention. Therefore, it is excluded. | 已完成 |
| Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes Obes Metab | PMID 39996356PMC11965027 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial.Diabet Med已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。 | PMID 40013389PMC12006556 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.Diabetes Obes Metab | PMID 40013432PMC11964995 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial.Lancet Respir Med | PMID 40020692无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).J Allergy Clin Immunol Pract | PMID 40023371无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.Respir Med | PMID 40024335无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.Lancet Diabetes Endocrinol | PMID 40031941无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events.Am J Clin Nutr | PMID 40032221PMC12107494 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.Nat Med | PMID 40044930PMC12851417 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.Adv Ther | PMID 40048101PMC12006271 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CODIFI2: Randomised controlled trial to compare clinical and cost-effectiveness of swabs versus tissue sampling to inform management of infected diabetic foot ulcers.Diabet Med | PMID 40051068PMC12006554 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.Nat Med | PMID 40055521PMC12092258 | 2025-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.AIDS Behav | PMID 40063206PMC12031994 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.Nat Med | PMID 40065169PMC12092244 | 2025-May | 0.95 | The study is an eligible Phase III oncology RCT with drug intervention and original results, but the primary and key secondary endpoints are not time-to-event efficacy endpoints as required (they are response-based or continuous outcomes). Therefore, it is excluded from the KM digitization cohort. | 待处理 |
| Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.J Dermatol | PMID 40066907PMC12056280 | 2025-May | 0.95 | The study is a non-oncology (psoriasis) trial. Although it meets other criteria (phase 3, randomized, drug intervention, original results), it fails the fundamental oncology requirement for inclusion in this cohort. | 待处理 |
| Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.Diabetes Obes Metab | PMID 40069849PMC11964988 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Energy intake is associated with dietary macronutrient densities: inversely with protein and monounsaturated fat and positively with polyunsaturated fat and carbohydrate among postmenopausal females.Am J Clin Nutr | PMID 40088973PMC12107488 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial.Stroke | PMID 40123483无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial.Stroke | PMID 40123511PMC12037301 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.Nat Med | PMID 40133524PMC12951298 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study.Adv Ther | PMID 40169529PMC12006258 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.J Prev Alzheimers Dis | PMID 40189473PMC12184022 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.Lancet Psychiatry | PMID 40209740无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40220771无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial.Lancet Haematol | PMID 40222370无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up.Lancet Child Adolesc Health | PMID 40246359无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40250457无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.NEJM Evid疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40261119无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial.Cancer Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:瀑布图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。 | PMID 40272146PMC12020026 | 2025-May | 0.95 | The record is a subgroup/ad hoc analysis from the Phase III NETTER-1 trial. While it meets most eligibility criteria (oncology, human, randomized, Phase III, drug intervention, time-to-event endpoints), it is not an original formal-result report of the main trial, which is required for inclusion. It is a secondary analysis focusing on tumor shrinkage as a predictor, not the primary or key secondary efficacy result report. | 无 KM 图 |
| Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.Expert Rev Clin Immunol | PMID 40296516无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40306831无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.Lancet Haematol | PMID 40306832无 PMCID | 2025-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Infant mental health services for birth and foster families of maltreated pre-school children in foster care (BeST?): a cluster-randomized phase 3 clinical effectiveness trial.Nat Med | PMID 40312587PMC12092239 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.Future Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 3.:非 KM 图;另有 1 张未列出。 | PMID 40331625PMC12077470 | 2025-May | 0.90 | The study is an exploratory analysis of patient-reported adverse events from the CASPIAN trial. While it originates from a Phase III randomized trial with a drug intervention, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The focus is on safety/quality-of-life outcomes, which are excluded per criteria. | 无 KM 图 |
| Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图;Figure 5:森林图/亚组分析图。 | PMID 40334315PMC12167883 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO Clin Cancer Inform | PMID 40344545PMC12335010 | 2025-May | 0.85 | The record describes a prognostic analysis of an AI algorithm using data from Phase III randomized trials, but does not evaluate a drug intervention. It is an AI/diagnostic/prognostic study, not a drug efficacy trial. | 已完成 |
| Lipid-Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-Blind, Parallel, Multicenter, Phase 3 Clinical Trial.Clin Cardiol | PMID 40357888PMC12070249 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.Nephrology (Carlton) | PMID 40369895PMC12079003 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of mobile health technology combining telemonitoring and teleintervention versus usual care in vulnerable-phase heart failure management (HERMeS): a multicentre, randomised controlled trial.Lancet Digit Health | PMID 40374486无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.Alzheimers Dement | PMID 40390253PMC12089073 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Efinaconazole 10% Topical Solution for Treatment of Onychomycosis in Older Adults: A Post Hoc Analysis of Two Phase 3 Randomised Trials.Mycoses | PMID 40396391PMC12093445 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |